{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:46Z","timestamp":1787009866290,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To discuss recent advances in identification of biomarkers in systemic sclerosis for disease severity, prognosis, and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent reports describe novel circulating markers of disease severity, autoantibody associations with specific manifestations including cancer, and skin gene expression-based predictors of modified Rodnan skin score progression and treatment response. Moreover, there is converging evidence that C-reactive protein and pneumoproteins such as Krebs von den Lungen-6 and chemokine ligand 18 could serve as prognostic biomarkers in systemic sclerosis-associated interstitial lung disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Several novel biomarkers show promise in improving the assessment of systemic sclerosis (SSc) disease severity, prognosis, and treatment response. Their potential utility in prospective selection of patients for clinical trials and in individual patient management require additional research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000656","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T20:13:09Z","timestamp":1566418389000},"page":"595-602","source":"Crossref","is-referenced-by-count":28,"title":["Biomarkers in systemic sclerosis"],"prefix":"10.1097","volume":"31","author":[{"given":"Brian","family":"Skaug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.21964","article-title":"Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis","volume":"65","author":"Dore","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R5-20230828","doi-asserted-by":"crossref","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/BOR.0000000000000113","article-title":"Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement","volume":"26","author":"Domsic","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/BOR.0000000000000550","article-title":"An update on autoantibodies in scleroderma","volume":"30","author":"Mecoli","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/BOR.0000000000000324","article-title":"Emerging biomarkers in systemic sclerosis","volume":"28","author":"Manetti","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/BOR.0000000000000237","article-title":"Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data","volume":"28","author":"Martyanov","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41584-018-0021-9","article-title":"Existing and novel biomarkers for precision medicine in systemic sclerosis","volume":"14","author":"Wermuth","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/annrheumdis-2011-200883","article-title":"Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis","volume":"71","author":"Horn","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2016-210834","article-title":"Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis","volume":"77","author":"Beyer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/annrheumdis-2012-202843","article-title":"The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis","volume":"73","author":"Abignano","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R15-20230828","first-page":"254","article-title":"European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis","volume":"58","author":"Abignano","year":"2019","journal-title":"Rheumatology"},{"key":"R16-20230828","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23479","article-title":"Anti-RNPC3 (U11\/U12) antibodies in systemic sclerosis are associated with moderate to severe gastrointestinal dysmotility","author":"McMahan","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R17-20230828","first-page":"1179","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R18-20230828","doi-asserted-by":"crossref","DOI":"10.1002\/art.40893","article-title":"Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma","author":"Shah","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-019-1839-5","article-title":"Significance of antineutrophil cytoplasmic antibodies in systemic sclerosis","volume":"21","author":"Moxey","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","article-title":"Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study","volume":"77","author":"Herrick","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 113)","key":"R21-20230828","first-page":"126","article-title":"The role of inflammatory markers in assessment of disease activity in systemic sclerosis","volume":"36","author":"Ross","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2018-214778","article-title":"Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis","volume":"78","author":"Moon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","article-title":"Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin","volume":"138","author":"Hinchcliff","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/art.40656","article-title":"Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease","volume":"70","author":"Streicher","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R29-20230828","doi-asserted-by":"crossref","DOI":"10.1002\/art.40934","article-title":"Senescence signature in skin biopsies from systemic sclerosis patients treated with senolytic therapy: potential predictor of clinical response?","author":"Martyanov","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R32-20230828","doi-asserted-by":"crossref","DOI":"10.1002\/art.40898","article-title":"A machine learning classifier for assigning individual patients with systemic sclerosis to intrinsic molecular subsets","author":"Franks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/art.38101","article-title":"Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis","volume":"65","author":"Assassi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.160339","article-title":"Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease","volume":"43","author":"Kuwana","year":"2016","journal-title":"J Rheumatol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J Rheumatol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R38-20230828","doi-asserted-by":"crossref","DOI":"10.1002\/art.41020","article-title":"Pneumoproteins KL-6 and CCL-18 predict progression of interstitial lung disease in systemic sclerosis","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/1346-8138.14669","article-title":"Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: a longitudinal observational study","volume":"45","author":"Sumida","year":"2018","journal-title":"J Dermatol"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","article-title":"Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis","volume":"38","author":"Tiev","year":"2011","journal-title":"Eur Respir J"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3899\/jrheum.120997","article-title":"Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?","volume":"40","author":"Elhaj","year":"2013","journal-title":"J Rheumatol"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3899\/jrheum.170440","article-title":"High baseline serum clara cell 16 kDa predicts subsequent lung disease worsening in systemic sclerosis","volume":"45","author":"Riviere","year":"2018","journal-title":"J Rheumatol"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T02:01:11Z","timestamp":1693188071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000656","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}